Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 5/21/21 → 1/29/25 |
Financiación
- Merck Sharp & Dohme Corporation: 80.022,00 US$
MK5475-007: A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study To Evaluate The Efficacy And Safety Of MK-5475 In Adults With Pulmonary Arterial Hypertension
- Booth, David (PI)